Characteristics of Ischemic Versus Hemorrhagic Stroke in Patients Receiving Oral Anticoagulants: Results of the PASTA Study.
atrial fibrillation
intracerebral hemorrhage
ischemic stroke
non-vitamin K antagonist oral anticoagulant
vitamin K antagonist
Journal
Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241
Informations de publication
Date de publication:
15 Mar 2022
15 Mar 2022
Historique:
pubmed:
7
9
2021
medline:
19
3
2022
entrez:
6
9
2021
Statut:
ppublish
Résumé
Objective Limited data exist regarding the comparative detailed clinical characteristics of patients with ischemic stroke (IS)/transient ischemic attack (TIA) and intracerebral hemorrhage (ICH) receiving oral anticoagulants (OACs). Methods The prospective analysis of stroke patients taking oral anticoagulants (PASTA) registry, a multicenter registry of 1,043 stroke patients receiving OACs [vitamin K antagonists (VKAs) or non-vitamin K antagonist oral anticoagulant (NOACs)] across 25 medical institutions throughout Japan, was used. Univariate and multivariable analyses were used to analyze differences in clinical characteristics between IS/TIA and ICH patients with atrial fibrillation (AF) who were registered in the PASTA registry. Results There was no significant differences in cardiovascular risk factors, such as hypertension, diabetes mellitus, dyslipidemia, smoking, or alcohol consumption (all p>0.05), between IS/TIA and ICH among both NOAC and VKA users. Cerebral microbleeds (CMBs) [odds ratio (OR), 4.77; p<0.0001] were independently associated with ICH, and high brain natriuretic peptide/N-terminal pro B-type natriuretic peptide levels (OR, 1.89; p=0.0390) were independently associated with IS/TIA among NOAC users. A history of ICH (OR, 13.59; p=0.0279) and the high prothrombin time-international normalized ratio (PT-INR) (OR, 1.17; p<0.0001) were independently associated with ICH, and a history of IS/TIA (OR, 3.37; 95% CI, 1.34-8.49; p=0.0101) and high D-dimer levels (OR, 2.47; 95% CI, 1.05-5.82; p=0.0377) were independently associated with IS/TIA among VKA users. Conclusion The presence of CMBs, a history of stroke, natriuretic peptide and D-dimer levels, and PT-INR may be useful for risk stratification of either IS/TIA or ICH development in patients with AF receiving OACs.
Identifiants
pubmed: 34483213
doi: 10.2169/internalmedicine.8113-21
pmc: PMC8987259
doi:
Substances chimiques
Anticoagulants
0
Vitamin K
12001-79-5
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
801-810Références
J Neurol. 2017 Dec;264(12):2413-2419
pubmed: 29063241
J Stroke Cerebrovasc Dis. 2016 Aug;25(8):1901-6
pubmed: 27177921
J Stroke Cerebrovasc Dis. 2019 Dec;28(12):104456
pubmed: 31676161
J Am Coll Cardiol. 2007 Jul 24;50(4):309-15
pubmed: 17659197
Cerebrovasc Dis. 2020;49(2):144-150
pubmed: 32023609
Intern Med. 2001 Dec;40(12):1183-8
pubmed: 11813841
Circulation. 2007 May 29;115(21):2689-96
pubmed: 17515465
Chest. 2010 Nov;138(5):1093-100
pubmed: 20299623
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
Eur Heart J. 2021 Feb 1;42(5):373-498
pubmed: 32860505
N Engl J Med. 2005 Jun 2;352(22):2285-93
pubmed: 15930419
Eur Heart J. 2010 Oct;31(19):2369-429
pubmed: 20802247
J Stroke Cerebrovasc Dis. 2019 Apr;28(4):1007-1014
pubmed: 30612891
J Thromb Haemost. 2014 Sep;12(9):1401-12
pubmed: 24942912
Stroke. 2015 May;46(5):1187-95
pubmed: 25765726
Circ J. 2015;79(8):1841-5
pubmed: 25993997
Am J Cardiol. 2016 Jul 15;118(2):222-5
pubmed: 27289294
Thromb Haemost. 2016 May 2;115(5):921-30
pubmed: 26818781
J Cardiol. 2013 Apr;61(4):260-6
pubmed: 23403369
Circ J. 2008 Jun;72(6):909-13
pubmed: 18503215
Circ J. 2020 Apr 24;84(5):706-713
pubmed: 32213724
J Stroke Cerebrovasc Dis. 2011 Jul-Aug;20(4 Suppl):S1-6
pubmed: 21835351
Stroke. 2014 Sep;45(9):2805-7
pubmed: 25082810
Eur J Neurol. 2017 Nov;24(11):1399-1406
pubmed: 28799181
Circ J. 2015;79(2):339-45
pubmed: 25501801
Expert Opin Pharmacother. 2020 Dec;21(17):2115-2124
pubmed: 32749891
J Clin Med. 2019 Sep 13;8(9):
pubmed: 31540205
Int J Stroke. 2015 Aug;10(6):836-42
pubmed: 25581108
Clin Pharmacol Ther. 2003 Mar;73(3):253-63
pubmed: 12621390
J Neurol. 2019 Sep;266(9):2263-2272
pubmed: 31165232
Chest. 2013 Dec;144(6):1839-1847
pubmed: 24009027
Stroke. 2018 Jul;49(7):1737-1740
pubmed: 29880555
Circ J. 2016 Sep 23;80(10):2089-91
pubmed: 27581348
Neurology. 2016 Oct 4;87(14):1501-1510
pubmed: 27590288
Heart. 2015 Aug;101(15):1204-11
pubmed: 26037103
J Stroke Cerebrovasc Dis. 2018 May;27(5):1338-1342
pubmed: 29397310
J Neurol Sci. 2009 Jun 15;281(1-2):55-7
pubmed: 19321180
J Neurol Neurosurg Psychiatry. 2005 May;76(5):679-83
pubmed: 15834026
Circulation. 2019 Jul 9;140(2):e125-e151
pubmed: 30686041
Stroke. 2013 Apr;44(4):995-1001
pubmed: 23493732
Lancet. 2014 Mar 15;383(9921):955-62
pubmed: 24315724